Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC

Farrah B. Khan, MD; Pamela C. Gibson, MD; Scott Anderson, MD; Sarah Wagner, BS; Bernard F. Cole, PhD; Peter Kaufman, MD; C. Matthew Kinsey, MD, MPH

JTO Clinical and Research Reports (Mar 2024)

Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC

Farrah B. Khan, MD,
Pamela C. Gibson, MD,
Scott Anderson, MD,
Sarah Wagner, BS,
Bernard F. Cole, PhD,
Peter Kaufman, MD,
C. Matthew Kinsey, MD, MPH

Affiliations

Farrah B. Khan, MD: Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont
Pamela C. Gibson, MD: Department of Pathology & Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont
Scott Anderson, MD: Department of Pathology & Laboratory Medicine, University of Vermont College of Medicine, Burlington, Vermont
Sarah Wagner, BS: Division of Pulmonary and Critical Care, Larner College of Medicine at the University of Vermont, Burlington, Vermont
Bernard F. Cole, PhD: Department of Mathematics and Statistics, University of Vermont, Burlington, Vermont
Peter Kaufman, MD: Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont
C. Matthew Kinsey, MD, MPH: Division of Pulmonary and Critical Care, Larner College of Medicine at the University of Vermont, Burlington, Vermont; Corresponding author. Address for correspondence: C. Matthew Kinsey, MD, MPH, Division of Pulmonary and Critical Care, Larner College of Medicine at the University of Vermont, 89 Beaumont Avenue, Given D208, Burlington, VT, 05401.

Journal volume & issue: Vol. 5, no. 3
p. 100634

Abstract

Read online

Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through endobronchial ultrasound bronchoscopy, in the same procedure as the initial diagnosis. There were no dose-limiting toxicity identified at the 20mg level

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords